|
| (R)-BAY1238097 Basic information |
Product Name: | (R)-BAY1238097 | Synonyms: | (R)-BAY1238097;3H-2,3-Benzodiazepine-3-carboxamide, 4,5-dihydro-7,8-dimethoxy-N,4-dimethyl-1-[4-(4-methyl-1-piperazinyl)phenyl]-, (4R)-;(R)BAY1238097,(R) BAY1238097,(R)-BAY-1238097 | CAS: | 1564269-85-7 | MF: | C25H33N5O3 | MW: | 451.56 | EINECS: | | Product Categories: | | Mol File: | 1564269-85-7.mol | ![(R)-BAY1238097 Structure](CAS/20200515/GIF/1564269-85-7.gif) |
| (R)-BAY1238097 Chemical Properties |
density | 1.22±0.1 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | DMSO : 150 mg/mL (332.18 mM);Water : < 0.1 mg/mL (insoluble) | form | Solid | pka | 15.43±0.60(Predicted) | color | Light yellow to yellow |
| (R)-BAY1238097 Usage And Synthesis |
Description | (R)-BAY1238097 is the R-isomer with lower activity of BAY1238097. BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome[1][2].
BET[1]. | References | [1]. Lejeune, P., et al. (2015) Abstract 3524: BAY 1238097, a novel BET inhibitor with strong efficacy in hematological tumor models. Cancer Research, 75(15 Suppl), 884.
[2]. Bernasconi E, et al. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948. |
| (R)-BAY1238097 Preparation Products And Raw materials |
|